Fig. 1

The three countries studied differ substantially in the HRQoL scales preferred and in how this evidence is assessed. Comparison of HAS [12], NICE [23] and IQWiG [15] methods guides, including an overall assessment of the approach, acceptance of open-label data, requirements for end-point hierarchy, acceptance of real-world evidence, preference of generic or disease-specific HRQoL scales, requirements for instrument validations, thresholds for minimum clinically important difference (MCID) and guidelines for missing data